Introduction: The age of the population in Saudi Arabia is shifting toward elderly, which can lead to an increased risk of mild cognitive impairment (MCI) and dementia. Objective: The aim of this study is to determine the prevalence of cognitive impairment (MCI and dementia) among elderly patients in a community-based setting in Riyadh, Saudi Arabia. Methods: In this cross-sectional study, we included patients aged 60 years and above who were seen in the Family Medicine Clinics affiliated with King Faisal Specialist Hospital and Research Centre. Patients with delirium, active depression, and patients with a history of severe head trauma in the past 3 months were excluded. Patients were interviewed during their regular visit by a trained physician to collect demographic data and to administer the validated Arabic version of the Montreal Cognitive Assessment (MoCA) test. Results: One hundred seventy-one Saudi patients were recruited based on a calculated sample size for the aim of this study. The mean age of included sample was 67 ± 6 years. The prevalence of cognitive impairment was 45%. The prevalence of MCI was 38.6% and the prevalence of dementia was 6.4%. Age, low level of education, hypertension, and cardiovascular disease were risk factors for cognitive impairment. Conclusion: Prevalence of MCI and dementia in Saudi Arabia using MoCA were in the upper range compared to developed and developing countries. The high rate of risk factors for cognitive impairment in Saudi Arabia is contributing to this finding.

The age of the Saudi population is shifting toward elderly. In 2016, the number of people over 60 years of age was 1.3 million (6.5 percent) and by 2050, this age group will exceed 10 million, representing 25% of the total population [1, 2]. In addition, the life expectancy in the country is expected to move from 74 to 82 years [1]. With this rise in longevity, the risk of developing cognitive impairment is expected to increase [3]. Moreover, the prevalence of dementia worldwide is expected to triple over the next two decades [4].

Mild cognitive impairment (MCI) is a transitional stage prior to dementia, with preserved daily life activities [5]. The annual conversion rate to dementia reaches up to 20% [6]. Early diagnosis of dementia can help in slowing the progress of the disease, which can result in significant benefits for both the patient and the caregiver [7].

The studies evaluating prevalence of dementia and MCI in Arab countries and the Gulf region is scarce. There are no published studies about the prevalence of MCI and dementia in Saudi Arabia. Our aim in this study is to evaluate the prevalence of MCI and dementia using a validated Arabic version of the Montreal Cognitive Assessment (MoCA) test [8, 9]. In addition, we aim to identify important risk factors for MCI and dementia among the Saudi population.

In this cross-sectional study, patients were recruited from the Family Medicine Clinics affiliated with King Faisal Specialist Hospital and Research Centre (KFSHRC) during the patients’ regular visit. We included male and female individuals aged 60 years and above. Patients with delirium, active depression, and patients with a history of severe head trauma in the past 3 months were excluded. Verbal consent was obtained from all participants and the study was approved by the Institution Review Board and Ethics Committee at KFSHRC.

The MoCA instrument is one of the validated instruments for the screening and diagnosis of MCI and dementia. In addition, the Arabic version of MoCA that we used was validated [9]. MoCA score ranges between 0 and 30. One point is added if years of education are less than 12 years. Scores below 26 and 17 indicate MCI and dementia, respectively [7, 10, 11]. Permission for using MoCA has been granted by the author group. The MoCA questionnaire was completed by a trained physician for each included patient.

Our sample size was calculated based on an estimated prevalence of MCI of 20% [12], with type I error rate of 5% and 95% confidence with 6% error margin. The required sample size was 171 patients.

The investigators explained the study for each participant and obtained their verbal consent. If the patient agreed to participate in the study, one of the investigators (M.A.) interviewed the patient and filled out a questionnaire about their demographic data and medical history, and then administered the validated Arabic version of the MoCA test.

Statistical Analysis

All statistical analysis of data was done by using the software package SPSS, version 20. Descriptive statistics for the continuous variables were reported as means and standard deviations, and categorical variables were summarized as frequencies and percentages. Continuous variables were compared using the Student t test, while categorical variables were compared using the χ2 test. Regression was used to evaluate potential risk factors for cognitive impairment. The level of statistical significance was set at p < 0.05.

The study included 171 subjects, 57% of them were males and 43% were females. We found that 23% of subjects were illiterate. Almost a third of the subjects had memory problem complaints, 12% had a positive family history of dementia, and about 7% of the subjects had personal assistance (Table 1).

Table 1.

Study population demographics and characteristics (n = 171)

Study population demographics and characteristics (n = 171)
Study population demographics and characteristics (n = 171)

The prevalence of several risk factors for dementia (Table 2) was high among the included sample. Hypertension prevalence was 75%, diabetes was 60%. Using regression analysis (Table 3), we found age, low level of education, hypertension, and cardiovascular disease to be important risk factors for cognitive impairment.

Table 2.

Prevalence of risk factors among participants (n = 171)

Prevalence of risk factors among participants (n = 171)
Prevalence of risk factors among participants (n = 171)
Table 3.

Regression analysis of important risk factors of dementia (n = 171)

Regression analysis of important risk factors of dementia (n = 171)
Regression analysis of important risk factors of dementia (n = 171)

Using MoCA standard cutoff point less than 26 for MCI and 17 for dementia showed that 46 and 26% of included subjects had MCI and dementia, respectively. Overall, the prevalence of cognitive impairment was 72.5% based on the standard MoCA cutoff point. The original validation of the MoCA score was conducted in a highly educated population. To adjust for the level of education, a validated education-adjusted cutoff score was applied in our study [13].

The adjusted cutoff points for MCI were less than 14 for illiterate individuals, less than 20 for individuals with 1–6 years of education, and less than 25 for individuals with 7 or more years of education. The adjusted cutoff scores for dementia were less than 9 for illiterate individuals, less than 13 for individuals with 1–6 years of education, and less than 16 for individuals with 7 or more years of education. Based on the level of education-adjusted score, the prevalence of MCI and dementia was 38.6 and 6.4%, respectively, and the overall prevalence of cognitive impairment was 45%.

The prevalence of dementia and MCI differs worldwide because of multiple factors including the variation of educational levels, and the prevalence of other important risk factors of dementia [14, 15]. The estimated global prevalence of dementia in elderly above the age of 60 is 5–7% [16]. On the other hand, the prevalence of MCI ranges between 10 and 20% [17]. Regionally, the prevalence of cognitive impairment for both dementia and MCI among Arabic speaking populations are substantially varied and ranges between 4.4 and 32% [18-20]. This is the first study evaluating the prevalence of cognitive impairment in a community-based setting in Saudi Arabia and the region using MoCA.

Age, low level of education, smoking, obesity, diabetes mellitus, hypertension, and high cholesterol are all considered risk factors for dementia [21]. Data from Saudi Arabia shows high prevalence of these risk factors [12]. Among the general adult population, the prevalence of hypertension and hypercholesterolemia is estimated to be 26 and 50%, respectively [22, 23]. In addition, obesity is a major health issue in Saudi Arabia with very high prevalence reaching up to 35% [24]. Furthermore, diabetes mellitus prevalence is 23% [25]. The prevalence of hypertension and diabetes in our study is consistent with the morbidity profile among the elderly population in Saudi Arabia as reported in other studies [26]. In the Arabic validation study, the prevalence of cognitive impairment was 34 and 44% for male and female subjects, respectively [9].

It has been consistently suggested that one cutoff point is not ideal, especially for educationally diverse population. Even more, level of education is considered one of the strongest factors affecting MoCA score [13]. In our study, the level of illiteracy is significantly higher than in the original study validating MoCA and the Arabic MoCA validation study. The illiteracy rate among the included sample is matching the illiteracy rate among the general elderly population in Saudi Arabia [2].

The mean age in our study is lower than the mean age of other studies evaluating the prevalence of cognitive impairment in other countries. The worldwide prevalence of dementia among the general population for the same age group as in our study is 4%, while it is 6.4% in our study.

Finally, MCI and dementia prevalence in our study were higher than the worldwide figures. This high prevalence of cognitive impairment despite the included relatively young elderly population is related to the high level of illiteracy and the high prevalence of risk factors of dementia. There is a need to control risk factors of cognitive impairment in Saudi Arabia such as diabetes, hypercholesterolemia, and hypertension; otherwise the prevalence of dementia could increase significantly in the country as the aging population increases.

We would like to thank Ms. Suad Alsoghayer and Mr. Abdelmoneim Eldali for their great support and help.

The authors declare no conflict of interest.

1.
Abusaaq H: Population Aging in Saudi Arabia [Internet]. 1st ed. Economic Research Department, Saudi Arabian Monetary Agency; 2015 (cited July 12, 2017). Available from: http://www.sama.gov.sa/en-US/EconomicResearch/WorkingPapers/population%20aging%20in%20saudi%20arabia.pdf.
2.
Demographic Survey 2016 (Internet). The General Authority for Statistics. 2016 (cited July 12, 2017). Available from: https://www.stats.gov.sa/sites/default/files/en-demographic-research-2016_2.pdf.
3.
Batum K, Çinar N, Şahin Ş, Çakmak M, Karşidağ S: The connection between MCI and Alzheimer disease: neurocognitive clues. Turk J Med Sci 2015; 45: 1137–1140.
4.
Norton S, Matthews F, Barnes D, Yaffe K, Brayne C: Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 2014; 13: 788–794.
5.
Lin J, O’Connor E, Rossom R, Perdue L, Eckstrom E: Screening for cognitive impairment in older adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 159: 601–612.
6.
Etgen T, Sander D, Bickel H, Förstl H: Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int 2011; 108: 743–750.
7.
Mukadam N, Cooper C, Kherani N, Livingston G: A systematic review of interventions to detect dementia or cognitive impairment. Int J Geriatr Psychiatry 2014; 30: 32–45.
8.
Nasreddine Z, Phillips N, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699.
9.
Rahman T, El Gaafary M: Montreal Cognitive Assessment Arabic version: reliability and validity prevalence of mild cognitive impairment among elderly attending geriatric clubs in Cairo. Geriatr Gerontol Int 2009; 9: 54–61.
10.
Horton D, Hynan L, Lacritz L, Rossetti H, Weiner M, Cullum C: An Abbreviated Montreal Cognitive Assessment (MoCA) for Dementia Screening. Clin Neuropsychol 2015; 29: 413–425.
11.
Trzepacz P, Hochstetler H, Wang S, Walker B, Saykin A: Relationship between the Montreal Cognitive Assessment and Mini-Mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr 2015; 15: 107.
12.
Memish Z, Jaber S, Mokdad A, AlMazroa M, Murray C, Al Rabeeah A: Burden of disease, injuries, and risk factors in the Kingdom of Saudi Arabia, 1990–2010. Prev Chronic Dis 2014; 11:E169.
13.
Lu J, Li D, Li F, Zhou A, Wang F, Zuo X, et al: Montreal Cognitive Assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. J Geriatr Psychiatry Neurol 2011; 24: 184–190.
14.
Rizzi L, Rosset I, Roriz-Cruz M: Global epidemiology of dementia: Alzheimer’s and vascular types. Biomed Res Int 2014; 2014: 908915.
15.
Sachs-Ericsson N, Blazer D: The new DSM-5 diagnosis of mild neurocognitive disorder and its relation to research in mild cognitive impairment. Aging Ment Health 2015; 19: 2–12.
16.
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri C: The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63–75.e2.
17.
Langa K, Levine D: The diagnosis and management of mild cognitive impairment. JAMA 2014; 312: 2551.
18.
Sweed H, Elawam A: Cognitive impairment among residents of elderly homes in Cairo, Egypt. Middle East J Psychiatry Alzheimers 2010; 1: 15–20.
19.
Afgin A, Massarwa M, Schechtman E, Israeli-Korn S, Strugatsky R, Abuful F, et al: High prevalence of mild cognitive impairment and Alzheimer’s disease in Arabic villages in northern Israel: impact of gender and education. J Alzheimers Dis 2012; 29: 431–439.
20.
Zaitoun A, Al Ma’moun A, Sarhan M, Selim A, Mousa G: Epidemiological study of dementia after retirement. Egypt J Neurol Psychiat Neurosurg 2008; 45: 65–74.
21.
Alzheimer’s Association: 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 2015; 11: 332–384.
22.
Al-Nozha MM, Arafah MR, Al-Maatouq MA, Khalil MZ, Khan NB, Al-Marzouki K, Al-Mazrou YY, Abdullah M, Al-Khadra A, Al-Harthi SS, Al-Shahid MS, Al-Mobeireek A, Nouh MS: Hyperlipidemia in Saudi Arabia. Saudi Med J 2008; 29: 282–287.
23.
Al-Nozha MM, Abdullah M, Arafah MR, Khalil MZ, Khan NB, Al-Mazrou YY, Al-Maatouq MA, Al-Marzouki K, Al-Khadra A, Nouh MS, Al-Harthi SS, Al-Shahid MS, Al-Mobeireek A: Hypertension in Saudi Arabia. Saudi Med J 2007; 28: 77–84.
24.
Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, Khan NB, Al-Marzouki K, Abdullah MA, Al-Khadra AH, Al-Harthi SS, Al-Shahid MS: Obesity in Saudi Arabia. Saudi Med J 2005; 26: 824–829.
25.
Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al-Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A: Diabetes mellitus in Saudi Arabia. Saudi Med J 2004; 25: 1603–1610.
26.
Al-Modeer M, Hassanien N, Jabloun C: Profile of morbidity among elderly at home health care service in Southern Saudi Arabia. J Family Community Med 2013; 20: 53–57.
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.